Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

148
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
148
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

310
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
310
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

1.2K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.2K
Neural Regulation01:37

Neural Regulation

39.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.0K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

181
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
181

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Familial Aggregation of Parkinson Disease and Essential Tremor in Early and Late Onset Parkinson Disease Cohorts.

Neurology·2026
Same author

Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Increased VH4+JH6+ antibody heavy chain use in plasmablasts from asymptomatic multiple sclerosis patients.

Genes and immunity·2026
Same author

Multiple sclerosis controversies: Do MRI-negative relapses really exist? - Commentary.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Autonomic Dysfunction and Risk of Mortality in Early-Onset Parkinson's Disease.

Annals of neurology·2025
Same author

Skin Biopsy for Phosphorylated α-Synuclein in Mild Cognitive Impairment or Dementia Due to Lewy Body Disease in a Convenience Cohort from a Subspecialty Behavioral Neurology Practice.

Movement disorders : official journal of the Movement Disorder Society·2025
Same journal

Mortality rate, main causes of death and factors associated with higher mortality hazard in late stage Parkinson's disease.

Journal of Parkinson's disease·2026
Same journal

Abnormal motor control effort costs in Parkinson's disease patients with apathy.

Journal of Parkinson's disease·2026
Same journal

Deficits in episodic memory and executive functions in relation to CB1 receptor availability in Parkinson's disease.

Journal of Parkinson's disease·2026
Same journal

Rationale and current status of fecal microbiota transplantations for Parkinson's disease.

Journal of Parkinson's disease·2026
Same journal

Basal ganglia neurophysiological markers of non-motor symptoms in Parkinson's disease: A systematic review.

Journal of Parkinson's disease·2026
Same journal

Agreement between relatives of Parkinson's patients and clinical observer in home diary assessments.

Journal of Parkinson's disease·2026
See all related articles

Related Experiment Video

Updated: May 10, 2025

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

2.6K

Dopamine-responsive post-anoxic parkinsonism.

Tina Liu1, J Eric Ahlskog1, James Bower1

  • 1Department of Neurology, Mayo Clinic, Rochester, MN, USA.

Journal of Parkinson'S Disease
|April 24, 2025
PubMed
Summary
This summary is machine-generated.

Post-anoxic parkinsonism, a rare condition from hypoxic-ischemic brain damage, can improve with dopamine therapy. This case series highlights five patients who experienced symptom relief with dopaminergic agents.

Keywords:
akinetic-rigid syndromedopamineparkinsonismpost-anoxic

More Related Videos

Murine Model for Parkinson's Disease: from 6-OH Dopamine Lesion to Behavioral Test
08:06

Murine Model for Parkinson's Disease: from 6-OH Dopamine Lesion to Behavioral Test

Published on: January 15, 2010

31.5K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

3.6K

Related Experiment Videos

Last Updated: May 10, 2025

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

2.6K
Murine Model for Parkinson's Disease: from 6-OH Dopamine Lesion to Behavioral Test
08:06

Murine Model for Parkinson's Disease: from 6-OH Dopamine Lesion to Behavioral Test

Published on: January 15, 2010

31.5K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

3.6K

Area of Science:

  • Neurology
  • Neuroscience
  • Clinical Medicine

Background:

  • Parkinsonism can rarely occur after hypoxic-ischemic brain injury, particularly affecting the basal ganglia.
  • Improvement with dopaminergic therapy is infrequently reported in such cases.

Purpose of the Study:

  • To describe the clinical and imaging characteristics of five patients with post-anoxic parkinsonism.
  • To document the response of post-anoxic parkinsonism to dopaminergic treatment.

Main Methods:

  • A retrospective case series was conducted using the Mayo Clinic Data Management System (2000-2024).
  • Patient data, including clinical features, neuroimaging (MRI), and medication trials (dopaminergic agents), were reviewed.

Main Results:

  • Five patients with post-anoxic parkinsonism following hypoxic events were identified.
  • All patients presented with parkinsonian symptoms (bradykinesia, rigidity, tremor, postural instability).
  • Four patients received carbidopa/levodopa, and one received a dopamine agonist, with all showing parkinsonism improvement over a median follow-up of 4 years.

Conclusions:

  • Parkinsonism secondary to hypoxic-ischemic insult is uncommon.
  • This case series demonstrates a significant response to dopaminergic therapy in patients with post-anoxic parkinsonism, suggesting a potential treatment avenue.